ANIX Stock Forecast: Anixa Biosciences, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Anixa Biosciences, Inc. is $9. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 61 of 100 as at 18 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Anixa Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (83): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (40): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ANIX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ANIX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $7.00 → $6.00 |
| 30 June 2026 | D. Boral Capital | Assumes | Buy | $10 |
| 8 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 31 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 4 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 12 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 7 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 22 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 11 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 19 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 5 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 29 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 26 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 25 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Mar 2025 | Maxim Group | Initiates | Buy | — |
| 18 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ANIX.
This page is one stock. Monday covers all of them.
ANIX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ANIX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, Anixa Biosciences, Inc. returned −40.2% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ANIX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 6.4×
- EV / EBITDA
- —
Cheaper than 14% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −73.2%
- Return on assets
- −41.9%
- Dividend yield
- —
Higher than 17% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Anixa Biosciences, Inc. has a market value of $92.8M and an enterprise value of $77.9M.
Revenue in the twelve months to 31 July 2026: $0.0.
Net income over the same four quarters: −$10.5M.
Free cash flow in the twelve months to 31 July 2026: −$7.4M.
Anixa Biosciences, Inc. employs 4 people.
Data provided by Twelve Data
ANIX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ANIX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Anixa Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ANIX
What is the ANIX stock price forecast for 2026-2027?
The median 12-month analyst price target for Anixa Biosciences, Inc. is $9, with estimates ranging from $6 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ANIX stock a buy right now?
Of the 3 analysts covering Anixa Biosciences, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anixa Biosciences, Inc. 61 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ANIX?
As at 18 Nov 2026, Anixa Biosciences, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (83 of 100).
Will ANIX stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts is $9, and Ticker Nerd's factor model ranks Anixa Biosciences, Inc. 61 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ANIX stock forecast for 2030?
No analyst covering Anixa Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $14 over the next 12 months.
How has ANIX stock performed over the past year?
Anixa Biosciences, Inc. returned -40.2% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Anixa Biosciences, Inc. do?
Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The company develops cancer vaccines and cell-based immunotherapies, including programs centered on breast cancer, ovarian cancer, and other hard-to-treat solid tumors.
About Anixa Biosciences, Inc.
Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The company develops cancer vaccines and cell-based immunotherapies, including programs centered on breast cancer, ovarian cancer, and other hard-to-treat solid tumors. Its work includes vaccine platforms designed to stimulate immune responses against cancer-related targets and a CAR-T-based therapeutic approach aimed at oncology applications. Anixa Biosciences also explores complementary diagnostics and related research programs that support early detection and cancer management. Headquartered in San Jose, California, Anixa Biosciences serves the biotechnology and oncology markets through a pipeline of current products and development programs that address unmet needs in cancer care.
CEO Dr. Amit Kumar Ph.D. · 4 employees · United States · https://www.anixa.com